Supporting Evidence-Based Decisions About Pneumococcal Conjugate Vaccines

  • Post author:
  • Post category:Blog

Results of recent studies that we supported focusing on vaccination against Streptococcus pneumoniae, a Gram-positive bacterium that is responsible for the majority of community-acquired pneumonia, were recently published, providing more evidence for health departments to use when developing their pediatric vaccination strategies.

Continue ReadingSupporting Evidence-Based Decisions About Pneumococcal Conjugate Vaccines

Meet PREVAIL Team Member T. Maccarthy Kpaan, Human Resources Manager, Based in Liberia

  • Post author:
  • Post category:Team

Maccarthy looks forward to working with diverse groups of people and perspectives on various issues and is passionate not only for improving human resources management but also for connecting talented individuals with a rewarding workplace.

Continue ReadingMeet PREVAIL Team Member T. Maccarthy Kpaan, Human Resources Manager, Based in Liberia

Without Quality Data, We Cannot Develop Effective Vaccines and Therapies

Quality data are needed to ensure that vaccines and therapies in development are focused on the right targets and deliver the expected outcomes. In the midst of an outbreak, how do we ensure that we have access to patients at sites that are prepared to collect the high-quality data needed for regulatory approval?

Continue ReadingWithout Quality Data, We Cannot Develop Effective Vaccines and Therapies

The Sooner, the Better: Planning for FDA Pre-IND Review of COVID-19 Studies

COVID-19 is a perfect example of a novel disease for which there is an urgent need for both vaccines and therapies. To help reduce the application review timelines, the FDA issued guidance for Pre-IND meeting requests in May. We summarize the recommendations and provide advice from our regulatory affairs team.

Continue ReadingThe Sooner, the Better: Planning for FDA Pre-IND Review of COVID-19 Studies

Pandemic Experience Means Expert Guidance

When COVID-19 was declared a pandemic, the FHI Clinical team immediately grasped the challenges that the search for vaccines and treatments would present. We’ve been here before, addressing everything from the global threat of malaria to outbreaks of Ebola in West Africa, Zika in the Americas, and chikungunya in the Caribbean during the aftermath of Hurricane Maria. In this blog post, we describe the steps to take and the critical questions to ask.

Continue ReadingPandemic Experience Means Expert Guidance

Data: The Key to Effective Outbreak Responses

In times like the ongoing pandemic when information overload can happen very quickly, it is helpful to go back to basics. What data do we need to inform our response to a new infectious disease threat? In the presence of a novel virus for which we have little to no information, what is the best approach to minimize the risks? In this blog post, we discuss the importance of reliable data during outbreaks.

Continue ReadingData: The Key to Effective Outbreak Responses
Read more about the article Responsive Approaches: Adapting Our Work to the New Realities of COVID-19
Work desk with a lighted lamp and computers, working from home

Responsive Approaches: Adapting Our Work to the New Realities of COVID-19

As FHI Clinical begins supporting rapid start-up of clinical trials vital to containing the spread of COVID-19 and protecting the global community, we are also adapting our ongoing work to the new reality of this global pandemic. We are closely monitoring the situation on the ground in the countries where we work and repurposing team members to support COVID-19 response needs.

Continue ReadingResponsive Approaches: Adapting Our Work to the New Realities of COVID-19

Rapid Site Assessment and Recommendations for Clinical Trials of a New Malaria Treatment

Targeted geographic areas for the development of an antimalarial drug by Novartis included malaria-endemic regions in Africa and Asia, and Novartis requested assistance identifying and assessing potential clinical sites for their planned clinical trial. Our team conducted 38 rapid, in-depth, 2.5-day site feasibility assessments in the 18 countries.

Continue ReadingRapid Site Assessment and Recommendations for Clinical Trials of a New Malaria Treatment